Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 770.64 USD 1.04% Market Closed
Market Cap: 730.4B USD

EV/EBITDA
Enterprise Value to EBITDA

35.3
Current
47.2
Median
12.4
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
35.3
=
Enterprise Value
761.6B USD
/
EBITDA
21.6B USD
Market Cap EV/EBITDA
US
Eli Lilly and Co
NYSE:LLY
730.4B USD 35.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 13.5
CH
Roche Holding AG
SIX:ROG
210.1B CHF 9.5
CH
Novartis AG
SIX:NOVN
188.5B CHF 10.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 130.8
US
Merck & Co Inc
NYSE:MRK
201.7B USD 8.6
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
136.6B USD 7.5
FR
Sanofi SA
PAR:SAN
105.5B EUR 4.5
EBITDA Growth EV/EBITDA to Growth
US
Eli Lilly and Co
NYSE:LLY
Average EV/EBITDA: 394.6
35.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
13%
1
CH
Roche Holding AG
SIX:ROG
9.5
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7
FR
Sanofi SA
PAR:SAN
4.5
7%
0.6

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
29.2
2-Years Forward
EV/EBITDA
22.5
3-Years Forward
EV/EBITDA
18.5